Investigating the Contributions of Residues to Dipeptidyl Peptidase-IV Inhibitor Binding by Molecular Dynamics Simulation

Publisher： Bentham Science Publishers

E-ISSN： 1875-628x|11|7|886-893

ISSN： 1570-1808

Source： Letters in Drug Design & Discovery, Vol.11, Iss.7, 2014-08, pp. : 886-893

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacological profile of ASP8497, a novel, selective, and competitive dipeptidyl peptidase-IV inhibitor, in vitro and in vivo

By Someya Yuka  

Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 377, Iss. 3, 2008-05 ,pp. : 209-217

Springer Publishing Company

Access to resources Recommend Favorite

Human pharmacokinetic profiling of the dipeptidyl peptidase‐IV inhibitor teneligliptin using physiologically based pharmacokinetic modeling

By  

Biopharmaceutics And Drug Disposition, Vol. 36, Iss. 3, 2015-04 ,pp. : 148-162

John Wiley & Sons Inc

Access to resources Recommend Favorite

Molecular Recognition of Ligands in Dipeptidyl Peptidase IV

By  

Current Topics in Medicinal Chemistry, Vol. 7, Iss. 6, 2007-03 ,pp. : 609-620

Bentham Science Publishers

Access to resources Recommend Favorite

Preclinical development of dipeptidyl peptidase IV inhibitor alogliptin: a brief overview

By Parsa Kishore VL   Pal Manojit  

Expert Opinion on Drug Discovery, Vol. 6, Iss. 8, 2011-08 ,pp. : 855-869

Informa Healthcare

Access to resources Recommend Favorite

Novel Serine Protease Dipeptidyl Peptidase IV Inhibitor: Alogliptin

By  

Mini Reviews in Medicinal Chemistry, Vol. 12, Iss. 13, 2012-11 ,pp. : 1345-1358

Bentham Science Publishers

Access to resources Recommend Favorite